The Quantellect read.As of Nov 19, 2026, 21 active firms cover Merck & Company Inc: 16 rate it Buy or better, 5 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $120.00 to $180.00, a moderate spread. The average target of $158.85 sits 19% above the current $133.99. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 14 to 16 over recent months. On the fundamentals, the Street sees consensus EPS building from about $2.13 next quarter toward $8.96 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS21 active firms
Buy
Strong Buy00%
Buy1676%
Neutral524%
Sell00%
Strong Sell00%
Based on 21 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$158.85
+18.6% upside
Average target across 20 active firms as of Nov 19, 2026 vs $133.99 current
Highest Target$180.00
Average Target$158.85
Lowest Target$120.00
Detailed analyst forecasts for MRK
Showing 1–18 of 18 named analysts shown · 21 active firms in the rating projection
As of Nov 19, 2026, 16 of 21 active firms rate MRK a Buy (5 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
MRK EPS & revenue forecast
EPS · NEXT QUARTER
$2.13
Range $1.97 – $2.27 · 9 analysts · -266% YoY
Next period, 9 analysts expect Merck & Company Inc to earn $2.13 a share (range $1.97 – $2.27), versus $-1.28 a year earlier. Full-year consensus is $2.79, growing to $8.96 the year after.
REVENUE · NEXT QUARTER
$16.4B
Range $16.1B – $16.8B · 9 analysts · +1% YoY
Revenue is expected to reach $16.4B (range $16.1B – $16.8B), +1.0% year-over-year. Full-year consensus is $67.2B, rising to $69.5B next year.
Top analysts covering Merck & Company Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MRK.
#1
Jason Gerberry
B of A Securities · Rank #160
Buy
$165.00+23.1% to target
Overall win rate
47%
+ Follow
#2
Vamil Divan
Guggenheim · Rank #211
Buy
$171.00+27.6% to target
Overall win rate
48%
+ Follow
#3
Terence Flynn
Morgan Stanley · Rank #222
Buy
$174.00+29.9% to target
Overall win rate
36%
+ Follow
#4
CS
Chris Schott
JP Morgan · Rank #287
Buy
$175.00+30.6% to target
Overall win rate
41%
+ Follow
#5
Daina Graybosch
Leerink Partners · Rank #396
Buy
$162.00+20.9% to target
Overall win rate
41%
+ Follow
MRK stock forecast FAQ
What is MRK's average 12-month price target?+
The 20 active firms with a live target average $158.85 for Merck & Company Inc over the next 12 months, ranging from a $180.00 high to a $120.00 low, as of Nov 19, 2026.
Is MRK stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 21 active firms as of Nov 19, 2026, 16 rate it Buy or Strong Buy, 5 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for MRK?+
The Street-high target is $180.00 (Scotiabank), and the Street-low is $120.00 (TD Cowen). The average of all 20 active-firm targets is $158.85.
How many active Wall Street firms cover MRK?+
21 active firms have a recognized rating on Merck & Company Inc as of Nov 19, 2026, and 20 active firms carry a live 12-month price target.
Who is the most accurate analyst covering MRK?+
Among analysts who currently cover MRK, Jason Gerberry of B of A Securities has the strongest overall Quantellect track record (Rank #160). Their current call is Buy with a $165.00 target.
What is Merck & Company Inc's projected EPS for next quarter?+
The consensus estimate is $2.13 per share (range $1.97 – $2.27) across 9 analysts. Full-year EPS is projected at $2.79, rising to $8.96 the following year.
How much revenue is Merck & Company Inc expected to report next quarter?+
Consensus revenue is $16.4B (range $16.1B – $16.8B). Full-year revenue is projected at $67.2B, growing to $69.5B next year.
Have analysts been upgrading or downgrading MRK lately?+
As of Nov 19, 2026, 16 of 21 active firms rate MRK a Buy (5 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MRK calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.